section name header

Introduction ⬇

VA Class:AM110

ATC Class:J01CE01

AHFS Class:

Generic Name(s):

Penicillin G, a natural penicillin, is a β-lactam antibiotic.10,61

Uses ⬆ ⬇

[Section Outline]

Penicillin G potassium and penicillin G sodium are used parenterally when rapid and high concentrations of penicillin G are required, as in the treatment of endocarditis, meningitis, pericarditis, septicemia, severe pneumonia, or other serious infections caused by organisms susceptible to penicillin G.8,9,10,11,12,61,64,197

For additional information on the uses of penicillin G potassium and penicillin G sodium, see Uses in the Natural Penicillins General Statement 8:12.16.04.

Endocarditis !!navigator!!

IV penicillin G potassium or sodium is used for the treatment of endocarditis caused by susceptible Streptococcus pyogenes (group A β-hemolytic streptococci; GAS), other β-hemolytic streptococci (including groups C, H, G, L, and M), or S. pneumoniae .8,9,11,12 The American Heart Association (AHA) states that IV penicillin G is a reasonable regimen for the treatment of endocarditis caused by susceptible S. pyogenes , S. agalactiae † (group B streptococci; GBS), groups C and G streptococci, and highly penicillin-susceptible S. pneumoniae (penicillin MIC 0.1 mcg/mL or less), but concomitant use of gentamicin during the initial weeks of penicillin G treatment should be considered if endocarditis is caused by streptococci groups B, C, or G.450

For the treatment of endocarditis caused by viridans group streptococci† or nonenterococcal group D streptococci† (including S. gallolyticus † [formerly S. bovis ]) that are highly susceptible to penicillin (penicillin MIC 0.12 mcg/mL or less), AHA states that IV penicillin G (with or without gentamicin) is a regimen of choice.450,452 If endocarditis is caused by viridans group streptococci† or S. gallolyticus † relatively resistant to penicillin (penicillin MIC greater than 0.12 mcg/mL but less than 0.5 mcg/mL), AHA states that IV penicillin G should be used in conjunction with gentamicin.450,452 These recommendations include endocarditis involving native valves or prosthetic valves or other prosthetic material caused by these gram-positive bacteria.450

AHA states that IV penicillin G in conjunction with gentamicin is a reasonable regimen for the treatment of native valve endocarditis caused by viridans group streptococci†, Abiotrophia defectiva †, or Granulicatella † with penicillin MIC 0.5 mcg/mL or greater.450,452

For the treatment of endocarditis involving native valves or prosthetic valves or other prosthetic material caused by Enterococcus faecalis †, E. faecium †, or other enterococcal species susceptible to both penicillin G and gentamicin, AHA states that IV penicillin G in conjunction with gentamicin is a regimen of choice.450,452 AHA states that it is reasonable to substitute streptomycin for gentamicin in this regimen if enterococci are susceptible to penicillin and streptomycin, but resistant to gentamicin.450

IV penicillin G has been used for the treatment of endocarditis caused by nonpenicillinase-producing staphylococci.8,9,11,12,452 AHA states that IV penicillin G may be considered for the treatment of native valve endocarditis caused by penicillin-susceptible S. aureus or coagulase-negative staphylococci in pediatric patients;452 however, penicillin G is not included in current AHA recommendations for the treatment of staphylococcal endocarditis in adults.450

AHA recommends that treatment of endocarditis should be managed in consultation with an infectious disease expert, especially when endocarditis is caused by S. pneumoniae , β-hemolytic streptococci, staphylococci, or enterococci.450,452

For additional information on management of endocarditis, current guidelines from AHA should be consulted.450,452

Syphilis !!navigator!!

IV penicillin G potassium or sodium is used for the treatment of syphilis caused by Treponema pallidum .8,9,11,12,344,345,350,440,441

For the treatment of neurosyphilis and otic or ocular syphilis, the US Centers for Disease Control and Prevention (CDC) and other clinicians state that IV penicillin G potassium or sodium is the drug of choice and IM penicillin G procaine (with oral probenecid) is an alternative if compliance can be ensured.344,345,440,441

For the treatment of congenital syphilis, CDC recommends IV penicillin G potassium or sodium or IM penicillin G procaine in neonates with proven or highly probable congenital syphilis (i.e., abnormal physical examination consistent with congenital syphilis, serum quantitative nontreponemal serologic titer fourfold higher than the mother's titer, or positive darkfield test or polymerase chain reaction [PCR] of lesions or body fluids).344 CDC recommends IV penicillin G potassium or sodium, IM penicillin G procaine, or IM penicillin G benzathine in neonates with possible congenital syphilis (i.e., normal physical examination and serum quantitative nontreponemal serologic titer no more than fourfold higher than the mother's titer and the mother received a recommended treatment regimen less than 4 weeks before delivery; the mother was not treated or was inadequately treated, including treatment with erythromycin or any regimen not included in CDC recommendations; or there is no documentation that the mother received treatment).344

CDC and other clinicians state that IM penicillin G benzathine is the drug of choice for the treatment of primary syphilis (i.e., ulcer or chancre at infection site), secondary syphilis (i.e., manifestations that include, but are not limited to, rash, mucocutaneous lesions, and lymphadenopathy), and tertiary syphilis (i.e., cardiac syphilis, gummatous lesions, tabes dorsalis, and general paresis) in adults, adolescents, and children.344,345,350,440,441

IM penicillin G benzathine also is the drug of choice for the treatment of latent syphilis (i.e., detected by serologic testing but lacking clinical manifestations), including both early latent syphilis (latent syphilis acquired within the preceding year) and late latent syphilis (i.e., all other cases of latent syphilis or syphilis of unknown duration) in all age groups.344,345,350,440,441

Neonates with human immunodeficiency virus (HIV) infection who have congenital syphilis and HIV-infected children, adolescents, or adults who have neurosyphilis or primary, secondary, early latent, late latent, or tertiary syphilis should receive the same treatment regimens as those without HIV infection.344,440,441 Because serologic nonresponse and neurologic complications may be more frequent in HIV-infected individuals, close follow-up is essential in those coinfected with syphilis and HIV.344,440 In addition, careful neurologic examinations are indicated in all HIV-infected patients coinfected with syphilis.440

There are no proven alternatives to penicillin G for the treatment of congenital syphilis in infants and children with known or suspected penicillin hypersensitivity and no proven alternatives to penicillin G for the treatment of any stage of syphilis in pregnant women with penicillin hypersensitivity; therefore, CDC recommends that such patients be desensitized and treated with the appropriate penicillin G preparation.344

For additional information on management of syphilis, current CDC sexually transmitted diseases treatment guidelines available at [Web] should be consulted.344

Prevention of Perinatal Group B Streptococcal Disease !!navigator!!

IV penicillin G potassium or sodium is used in pregnant women during labor (intrapartum) for prevention of early-onset neonatal group B streptococcal (GBS) disease†.292,359,362

GBS infection is a leading cause of neonatal morbidity and mortality in the US.362 Pregnant women who are colonized with GBS in the genital or rectal areas can transmit GBS infection to their infants during labor and delivery, resulting in invasive neonatal infection that can be associated with substantial morbidity and mortality.292,359,362

CDC, AAP, and other experts recommend routine universal prenatal screening for GBS colonization (e.g., vaginal and rectal cultures) in all pregnant women at 35-37 weeks of gestation, unless GBS bacteriuria is known to be present during the current pregnancy or the woman had a previous infant with invasive GBS disease.292,359 These experts state that intrapartum anti-infective prophylaxis for prevention of perinatal GBS is indicated in pregnant women identified as GBS carriers during the routine prenatal GBS screening performed at 35-37 weeks during the current pregnancy, in women with GBS bacteriuria identified at any time during the current pregnancy, and in women who had a previous infant diagnosed with invasive GBS disease.292,359 Intrapartum anti-infective prophylaxis also is indicated in women with unknown GBS status at the time of onset of labor (i.e., culture not done, incomplete, or results unknown) if delivery is at less than 37 weeks of gestation, the duration of amniotic membrane rupture is 18 hours or longer, or intrapartum temperature is 38°C or higher.292,359 If an intrapartum nucleic acid amplification test (NAAT) is performed in a woman with unknown GBS status at the time of onset of labor (may not be available in all settings) and results are positive for GBS, intrapartum anti-infective prophylaxis is indicated;359 if an intrapartum NAAT is negative for GBS, anti-infective prophylaxis is indicated if any of the above risk factors for perinatal GBS infection are present.359

When intrapartum anti-infective prophylaxis is indicated in the mother for prevention of GBS in the neonate, it should be initiated at the onset of labor or rupture of membranes.359 If cesarean delivery is performed before onset of labor in a woman with intact amniotic membranes, anti-infective prophylaxis is not usually indicated, regardless of the GBS colonization status of the woman or gestational age.292,359

CDC, AAP, and other experts recommend IV penicillin G as the drug of choice and state that IV ampicillin is the preferred alternative for such prophylaxis.292,359,362 Penicillin G is considered the drug of choice because it has a narrower spectrum of activity than ampicillin and is less likely to select for antibiotic-resistant organisms.292,359

Regardless of whether the mother received intrapartum anti-infective prophylaxis, appropriate diagnostic evaluations and anti-infective therapy should be initiated in the neonate if signs or symptoms of active infection develop.292,359,362

For additional information regarding prevention of perinatal group B streptococcal disease, current guidelines from CDC and AAP should be consulted.359,362

Dosage and Administration ⬆ ⬇

[Section Outline]

Reconstitution and Administration !!navigator!!

Penicillin G potassium and penicillin G sodium are administered by IM injection or by intermittent IV injection or infusion or continuous IV infusion.8,9,11,12,61 Penicillin G has been administered by intrapleural,9,12 intraperitoneal,61 intra-articular,9,12 or other local instillations.9,12 Although the drug has been administered intrathecally,9,12,61 this route is not recommended because of possible neurotoxicity (e.g., seizures).61,416

Vials containing penicillin G potassium or penicillin G sodium powder for injection should be reconstituted to the desired concentration using the amount of diluent specified by the manufacturer.8,9,12 Depending on the specific product and route of administration, the powders generally are reconstituted with sterile water for injection,8,9,12 0.9% sodium chloride injection,8,9,12 or dextrose injection.8 The powder should be loosened in the vial and the vial held horizontally and rotated while slowly directing the stream of diluent against the wall of the vial.8,9,12 After the diluent has been added, the vial should be shaken vigorously.8,9,12 Because penicillin G is unstable in solutions at room temperature,61 reconstituted penicillin G potassium and penicillin G sodium solutions should be used immediately or refrigerated.8,9,12 (See Chemistry and Stability: Stability.)

IM Injection

To prepare solutions for IM administration, vials labeled as containing 1 or 5 million units of penicillin G (as penicillin G potassium)9,12 or vials labeled as containing 5 million units of penicillin G (as penicillin G sodium)8 should be reconstituted to the desired concentration using the amount of diluent specified by the manufacturer.8,9,12 If not used immediately, vials reconstituted for IM use should be refrigerated (see Chemistry and Stability: Stability).8,9,12

Vials labeled as containing 20 million units of penicillin G (as penicillin G potassium) are intended only for IV infusion and should not be used to prepare solutions for IM injection.9,12

For IM administration, penicillin G potassium solutions containing up to 100,000 penicillin G units/mL may be used with a minimum of discomfort;9,12 higher concentrations are physically possible and may be used when needed.9,12

If large doses of penicillin G are required, the drug should be administered IV (not IM).9,12

IV Administration

To prepare solutions for IV administration, vials labeled as containing 1, 5, or 20 million units of penicillin G (as penicillin G potassium) or 5 million units of penicillin G (as penicillin G sodium) should be reconstituted according to the manufacturer's directions.8,9,12 If not used immediately, vials reconstituted for IV use should be refrigerated (see Chemistry and Stability: Stability).8,9,12

For intermittent IV administration, the daily dosage usually is given in equally divided doses every 4-6 hours; however, daily dosage may be given in equally divided doses every 2-3 hours for the treatment of severe infections (e.g., meningitis).8,9,12,61

For continuous IV infusion, the volume of IV fluid and rate of administration required by the patient in a 24-hour period should be determined and the appropriate daily dosage of penicillin G should be added to the fluid.9,12 For example, if an adult patient requires 2 L of fluid in 24 hours and a dosage of 10 million penicillin G units daily, 5 million units can be added to 1 L of IV solution and the rate of administration adjusted so that the liter of fluid will be infused over 12 hours.9,12

Thawed solutions of the commercially available frozen premixed penicillin G potassium injection in dextrose should be administered only by IV infusion.11 The commercially available frozen injection should be thawed at room temperature (25°C) or under refrigeration (5°C);11 the injection should not be thawed by warming in a water bath or by exposure to microwave radiation.11 Precipitates that may have formed in the frozen injection usually will dissolve with little or no agitation when the injection reaches room temperature;11 potency is not affected.11 After thawing at room temperature, the injections should be agitated and the container checked for minute leaks by firmly squeezing the bag.11 The injection should be discarded if the container seals or outlet ports are not intact or leaks are found or if the solution is cloudy or contains a precipitate.11 Additives should not be introduced into the injection container.11 The premixed injection should not be used in series connections with other plastic containers since such use could result in air embolism from residual air being drawn from the primary container before administration of fluid from the secondary container is complete.11

Rate of Administration

Large IV doses of penicillin G potassium or sodium (greater than 10 million penicillin G units) should be administered slowly because of the potential for serious electrolyte disturbances from the potassium and/or sodium content of these preparations.8,9,11,12 (See Cautions: Adverse Effects.)

For intermittent IV administration, penicillin G potassium or sodium has been given by IV infusion over 1-2 hours8,9,11,12,61,1563 or by IV infusion over 10-30 minutes.61,1414 Although doses of the drug also have been injected IV over 3-5 minutes,8,9,11,12,61 large doses should be administered slowly.8,9,11,12

Dosage !!navigator!!

Dosage of penicillin G potassium and penicillin G sodium usually is expressed in terms of penicillin G units,8,9,11,12 but also has been expressed as mg of penicillin G.61

Pediatric Dosage

General Pediatric Dosage

Dosage of IM or IV penicillin G potassium or sodium for pediatric patients should be individualized and generally is based on weight and the severity of the infection.8,9,11,12

The manufacturers state that penicillin G potassium or sodium should not be used in pediatric patients requiring less than 1 million penicillin G units per dose.8,9,11,12

The American Academy of Pediatrics (AAP) states that the usual dosage of IV or IM penicillin G potassium or sodium in neonates 7 days of age or younger is 25,000-50,000 units/kg every 12 hours.292 In neonates 8-28 days of age, AAP recommends a dosage of 25,000-50,000 units/kg every 8 hours.292 Higher dosages may be necessary for the treatment of meningitis in neonates.292

In pediatric patients beyond the neonatal period, AAP states that the usual dosage of IV or IM penicillin G potassium or sodium is 100,000-150,000 units/kg daily given in 4 equally divided doses for the treatment of mild to moderate infections or 200,000-300,000 units/kg daily given in 4-6 equally divided doses for the treatment of severe infections.292 AAP states that the highest dosage recommended for pediatric patients beyond the neonatal period should be used for the treatment of meningitis.292

Endocarditis

For the treatment of native valve endocarditis caused by highly penicillin-susceptible streptococci (penicillin MIC 0.1 mcg/mL or less), including Streptococcus pyogenes (group A β-hemolytic streptococci; GAS), other β-hemolytic streptococci (e.g., groups C, G), S. agalactiae † (group B streptococci; GBS), viridans group streptococci†, or nonenterococcal group D streptococci† (e.g., S. gallolyticus † [formerly S. bovis ], S. equinus †), the American Heart Association (AHA) states that pediatric patients may receive IV penicillin G in a dosage of 200,000-300,000 units/kg daily (up to 12-24 million units daily) given in divided doses every 4 hours for 4 weeks.452

For the treatment of native valve endocarditis caused by streptococci that are relatively resistant to penicillin† (penicillin MIC greater than 0.1 but less than 0.5 mcg/mL), AHA states that pediatric patients may receive IV penicillin G in a dosage of 200,000-300,000 units/kg daily (up to 12-24 million units daily) given in divided doses every 4 hours for 4 weeks in conjunction with gentamicin (3-6 mg/kg daily IV in divided doses every 8 hours given concomitantly during the first 2 weeks of penicillin G treatment).452

For the treatment of native valve endocarditis caused by viridans group streptococci†, Abiotrophia †, or Granulicatella † with penicillin MIC 0.5 mcg/mL or greater, AHA states that pediatric patients may receive IV penicillin G in a dosage of 200,000-300,000 units/kg daily (up to 12-24 million units daily) given in divided doses every 4 hours for 4-6 weeks in conjunction with gentamicin (3-6 mg/kg IV daily in divided doses every 8 hours given concomitantly during the first 2 weeks of penicillin G treatment).452

For the treatment of endocarditis involving prosthetic valves or other prosthetic material caused by penicillin-susceptible viridans group streptococci†, other streptococci, Abiotrophia †, or Granulicatella † with penicillin MIC 0.1 mcg/mL or greater, AHA states that pediatric patients may receive IV penicillin G in a dosage of 200,000-300,000 units/kg daily (up to 12-24 million units daily) given in divided doses every 4 hours for 6 weeks in conjunction with gentamicin (3-6 mg/kg IV daily in divided doses every 8 hours given concomitantly for the entire 6 weeks of penicillin G treatment).452

For the treatment of enterococcal endocarditis† (native valve or prosthetic valve or other prosthetic material), AHA states that pediatric patients may receive IV penicillin G in a dosage of 200,000-300,000 units/kg daily (up to 12-24 million units daily) given in divided doses every 4 hours in conjunction with gentamicin (3-6 mg/kg IV daily in divided doses every 8 hours).452 The recommended duration of treatment with the 2-drug regimen is 4-6 weeks for native valve enterococcal endocarditis; a longer duration of treatment with both drugs is recommended if prosthetic valves or other prosthetic material is involved.452

If IV penicillin G is used for the treatment of endocarditis caused by susceptible S. aureus or coagulase-negative staphylococci (penicillin MIC 0.1 mcg/mL or less) in pediatric patients, AHA recommends a dosage of 200,000-300,000 units/kg daily (up to 12-24 million units daily) given in divided doses every 4 hours.452

The manufacturers recommend that pediatric patients with endocarditis caused by susceptible streptococci (including S. pyogenes , streptococci groups C, H, G, L, and M, or S. pneumoniae ) receive penicillin G potassium or sodium in a dosage of 150,000-300,000 units/kg daily given in divided doses every 4-6 hours.8,9,11,12

Meningitis and Other CNS Infections

For the treatment of meningitis caused by susceptible Listeria monocytogenes , the Infectious Diseases Society of America (IDSA) recommends that neonates 7 days of age or younger receive IV penicillin G in a dosage of 150,000 units/kg daily given in divided doses every 8-12 hours and that those 8-28 days of age receive a dosage of 200,000 units/kg daily given in divided doses every 6-8 hours;418 these experts recommend that treatment in neonates be continued for 2 weeks beyond the first sterile CSF culture or for at least 3 weeks, whichever is longer.418 In infants and children with L. monocytogenes meningitis, IDSA recommends a dosage of 300,000 units/kg daily given in divided doses every 4-6 hours for a duration of at least 21 days.418 Concomitant use of an aminoglycoside should be considered.418

For the treatment of meningitis caused by susceptible Neisseria meningitidis (penicillin MIC less than 0.1 mcg/mL), IDSA recommends that neonates 7 days of age or younger receive IV penicillin G in a dosage of 150,000 units/kg daily given in divided doses every 8-12 hours and that those 8-28 days of age receive a dosage of 200,000 units/kg daily given in divided doses every 6-8 hours;418 these experts recommend that treatment in neonates be continued for 2 weeks beyond the first sterile CSF culture or for at least 3 weeks, whichever is longer.418 In infants and children with N. meningitidis meningitis, a dosage of 300,000 units/kg daily (up to 12 million units daily) given in divided doses every 4-6 hours for a duration of 7 days has been recommended.292,418

For the treatment of meningitis caused by susceptible S. agalactiae † (group B streptococci; GBS), AAP recommends that neonates 7 days of age or younger receive IV penicillin G in a dosage of 250,000-450,000 units/kg daily given in 3 divided doses and that those older than 7 days of age receive a dosage of 450,000-500,000 units/kg daily given in 4 divided doses and states that treatment should be continued for at least 14 days.292 IDSA recommends that neonates 7 days of age or younger receive IV penicillin G in a dosage of 150,000 units/kg daily given in divided doses every 8-12 hours and that those 8-28 days of age receive a dosage of 200,000 units/kg daily given in divided doses every 6-8 hours;418 these experts recommend that treatment in neonates be continued for 2 weeks beyond the first sterile CSF culture or for at least 3 weeks, whichever is longer.418 In infants and children with S. agalactiae meningitis, IDSA recommends a dosage of 300,000 units/kg daily given in divided doses every 4-6 hours for a duration of 14-21 days.418 Concomitant use of an aminoglycoside should be considered.418

For the treatment of meningitis caused by susceptible S. pneumoniae , IDSA recommends that neonates 7 days of age or younger receive IV penicillin G in a dosage of 150,000 units/kg daily given in divided doses every 8-12 hours and that those 8-28 days of age receive a dosage of 200,000 units/kg daily given in divided doses every 6-8 hours;418 these experts recommend that treatment in neonates be continued for 2 weeks beyond the first sterile CSF culture or for at least 3 weeks, whichever is longer.418 AAP recommends that infants and children 1 month of age or older with S. pneumoniae meningitis receive IV penicillin G in a dosage of 250,000-400,000 units/kg daily given in divided doses every 4-6 hours.292 IDSA recommends that infants and children receive a dosage of 300,000 units/kg daily given in divided doses every 4-6 hours for a duration of 10-14 days.418

For the treatment of healthcare-associated ventriculitis and meningitis caused by susceptible Cutibacterium acnes † (formerly Propionibacterium acnes ), IDSA recommends that pediatric patients receive IV penicillin G in a dosage of 300,000 units/kg daily given in divided doses every 4-6 hours.416 The recommended treatment duration is 10 days in those with no or minimal CSF pleocytosis, normal CSF glucose, and few clinical symptoms or systemic features or 10-14 days in those with significant CSF pleocytosis, CSF hypoglycorrhachia, or clinical symptoms or systemic features.416

The manufacturers recommend that pediatric patients with meningitis caused by susceptible N. meningitidis or S. pneumoniae receive penicillin G potassium or sodium in a dosage of 250,000 units/kg daily (up to 12-20 million units daily) given in divided doses every 4 hours for 7-14 days.8,9,11,12

Respiratory Tract Infections

For the treatment of community-acquired pneumonia (CAP) caused by susceptible S. pyogenes (group A β-hemolytic streptococci; GAS) in pediatric patients 3 months of age or older, IDSA recommends that IV penicillin G be given in a dosage of 100,000-200,000 units daily in divided doses every 4-6 hours.513 For severe infections, 200,000-250,000 units/kg daily may be used.513

For the treatment of CAP caused by susceptible S. pneumoniae (penicillin MIC 2 mcg/mL or lower) in pediatric patients 3 months of age or older, IDSA recommends that IV penicillin G be given in a dosage of 200,000-250,000 units/kg daily in divided doses every 4-6 hours.513 AAP recommends that infants and children 1 month of age or older with nonmeningeal infections caused by S. pneumoniae receive penicillin G in a dosage of 250,000-400,000 units/kg daily given in divided doses every 4-6 hours.292 Penicillin G should not be used for empiric treatment of CAP if local epidemiologic data indicate that invasive S. pneumoniae have high-level penicillin resistance.513

If penicillin G potassium or sodium is used for the treatment of serious respiratory tract infections (e.g., pneumonia) caused by susceptible S. pyogenes , streptococci groups C, H, G, L, and M, or S. pneumoniae , in pediatric patients, the manufacturers recommend a dosage of 150,000-300,000 units/kg daily in divided doses every 4-6 hours.8,9,11,12

Skin and Skin Structure Infections

For the treatment of necrotizing infections of the skin, fascia, and muscle caused by susceptible S. pyogenes , IDSA recommends that pediatric patients receive a regimen of IV penicillin G given in a dosage of 60,000-100,000 units/kg every 6 hours in conjunction with clindamycin (10-13 mg/kg IV every 8 hours).543

Anthrax

For the treatment of anthrax (inhalational, GI, meningitis) caused by penicillin-susceptible Bacillus anthracis that occurs as the result of natural or endemic exposures to anthrax, some clinicians recommend that children receive IV penicillin G in a dosage of 100,000-150,000 units/kg daily given in divided doses every 4-6 hours.670 For the treatment of severe or life-threatening systemic anthrax (inhalational, GI, meningoencephalitis, sepsis) or the treatment of cutaneous anthrax with signs of systemic involvement, lesions on the head or neck, or extensive edema caused by penicillin-susceptible B. anthracis that occurs as the result of natural or endemic anthrax exposure, some experts recommend that children receive IV penicillin G in a dosage of 300,000-400,000 units/kg daily given in divided doses every 4-6 hours.680 Concomitant use of other anti-infectives (e.g., streptomycin or other aminoglycoside, clindamycin, clarithromycin, rifampin, vancomycin) may also be indicated.670,680 Treatment of naturally occurring or endemic anthrax generally should be continued for at least 14 days after symptoms abate.670

If IV penicillin G is used in a multiple-drug parenteral regimen for initial treatment of systemic anthrax (inhalational, GI, meningitis, cutaneous anthrax with systemic involvement, lesions on the head or neck, or extensive edema) caused by penicillin-susceptible B. anthracis that occurs in the context of biologic warfare or bioterrorism, AAP states that full-term neonates 7 days of age or younger should receive a dosage of 300,000 units/kg daily given in divided doses every 8 hours and those 1-4 weeks of age should receive 400,000 units/kg daily given in divided doses every 6 hours.671 For the treatment of these systemic anthrax infections in premature neonates, AAP recommends that those with gestational age of 32-34 weeks receive 200,000 units/kg daily given in divided doses every 12 hours from birth until 7 days of age and 300,000 units/kg daily given in divided doses every 8 hours from 1-4 weeks of a 671 those with gestational age of 34-37 weeks should receive 300,000 units/kg daily given in divided doses every 8 hours from birth until 7 days of age and 400,000 units/kg daily given in divided doses every 6 hours from 1-4 weeks of age.671 In infants and children 1 month of age or older, AAP recommends that IV penicillin G be given in a dosage of 400,000 units/kg daily in divided doses every 4 hours (up to 4 million units per dose).671 The multiple-drug parenteral regimen should be continued for at least 2-3 weeks until the patient is clinically stable; treatment can then be switched to an oral regimen.671 Because of the possible persistence of anthrax spores in lung tissue following an aerosol exposure in the context of biologic warfare or bioterrorism, the US Centers for Disease Control and Prevention (CDC) and other experts state that the total duration of anti-infective treatment should be 60 days.668,671,683,686

For additional information on the treatment of anthrax and recommendations for postexposure prophylaxis following exposure to anthrax spores, see Uses: Anthrax, in Ciprofloxacin 8:12.18.

Clostridium Infections

For the treatment of myonecrosis and gas gangrene caused by Clostridium perfringens or other clostridium in children, IDSA recommends that IV penicillin G be given in a dosage of 60,000-100,000 units/kg every 6 hours in conjunction with clindamycin (10-13 mg/kg IV every 8 hours).543 AAP recommends that children with myonecrosis caused by C. perfringens receive IV penicillin G in a dosage of 250,000-400,000 units/kg daily and states that concomitant use of clindamycin may be more effective than penicillin G alone.292 Surgical debridement and/or surgery should be performed as indicated.8,9,11,12

If IV penicillin G is used as an adjunct to tetanus immune globulin (TIG) in the management of tetanus caused by C. tetani , AAP recommends that children receive a dosage of 100,000 units/kg daily (up to 12 million units daily) given in divided doses every 4-6 hours for 7-10 days.292 The role of anti-infectives in the adjunctive treatment of tetanus is unclear;10 metronidazole usually is preferred if an anti-infective is used.10,292

Diphtheria

If penicillin G potassium or sodium is used as an adjunct to diphtheria antitoxin (not commercially available in the US, but may be available from CDC) for the treatment of diphtheria caused by Corynebacterium diphtheriae and prevention of the diphtheria carrier state, the manufacturers recommend that pediatric patients receive a dosage of 150,000-250,000 units/kg daily given in divided doses every 6 hours for 7-10 days.8,9,11,12 CDC recommends a 14-day regimen of IM penicillin G procaine if a penicillin is used for adjunctive treatment of diphtheria.166 Patients usually are no longer contagious 48 hours after initiation of anti-infective treatment.166 Eradication of C. diphtheriae should be confirmed 24 hours after completion of treatment by 2 consecutive negative cultures taken 24 hours apart.166,292

Lyme Disease

If IV penicillin G is used as an alternative to IV ceftriaxone for the treatment of early Lyme disease† in children with acute neurologic disease manifested as meningitis or radiculopathy, IDSA recommends a dosage of 200,000-400,000 units/kg daily (up to 18-24 million units daily) given in divided doses every 4 hours for 10-28 days.329

If IV penicillin G is used as an alternative to IV ceftriaxone or IV cefotaxime for the treatment of late Lyme disease† in children with recurrent Lyme arthritis and objective evidence of neurologic disease, AAP and IDSA recommend a dosage of 200,000-400,000 units/kg daily (up to 18-24 million units daily) given in divided doses every 4 hours for 14-28 days.292,329

For the treatment of late neurologic Lyme disease† affecting the central or peripheral nervous system, IDSA, AAP, and others state that children can receive IV penicillin G in a dosage of 200,000-400,000 units/kg daily (up to 18-24 million units daily) given in divided doses every 4 hours for 14-28 days as an alternative to IV ceftriaxone.292,329,342 IDSA states that retreatment is not recommended unless relapse of neurologic disease is documented with reliable objective measures.329

Neisseria meningitidis Infections

For the treatment of serious infections (e.g. endocarditis, pneumonia) caused by susceptible N. meningitidis , the manufacturers recommend that pediatric patients receive penicillin G potassium or sodium in a dosage of 150,000-300,000 units/kg daily given in divided doses every 4-6 hours.8,9,11,12

For dosage recommendations for the treatment of meningitis caused by N. meningitidis in pediatric patients, see Meningitis and Other CNS Infections under Dosage: Pediatric Dosage, in Dosage and Administration.

Rat-Bite Fever

For the treatment of rat-bite fever caused by Streptobacillus moniliformis (erythema arthriticum epidemicum, Haverhill fever) or Spirillum minus (sodoku), the manufacturers recommend that pediatric patients receive penicillin G potassium or sodium in a dosage of 150,000-250,000 units/kg daily given in divided doses every 4 hours for 4 weeks.8,9,11,12

Some clinicians suggest that pediatric patients with rat-bite fever receive IV penicillin G in a dosage of 20,000-50,000 units/kg daily for 5-7 days followed by oral penicillin V (25-50 mg/kg daily [up to 3 g daily] in 4 divided doses for 7 days).30 For the treatment endocarditis caused by S. moniliformis strains that are less susceptible to penicillin G (MIC greater than 0.1 mcg/mL), some clinicians state that pediatric patients should receive IV penicillin G in a dosage of 160,000-240,000 units/kg daily (up to 20 million units daily) for 6 weeks;30 concomitant use of an aminoglycoside (streptomycin or gentamicin) may be indicated for initial treatment.10,30,292

Syphilis

For the treatment of proven or highly probable congenital syphilis in neonates (see Uses: Syphilis), CDC recommends an IV penicillin G dosage of 50,000 units/kg every 12 hours during the first 7 days of life and 50,000 units/kg every 8 hours thereafter for a total duration of 10 days.344 If more than 1 day of treatment is missed in such neonates, the entire course of treatment should be restarted.344 If IV penicillin G is used in neonates with possible congenital syphilis (see Uses: Syphilis), CDC recommends 50,000 units/kg every 12 hours during the first 7 days of life and 50,000 units/kg every 8 hours thereafter for a total duration 10 days.344

In infants and children 1 month of age or older with reactive serologic tests for syphilis, CDC recommends that IV penicillin G be given in a dosage of 200,000-300,000 units/kg daily (50,000 units/kg every 4-6 hours) for 10 days.344

CDC, AAP, and the manufacturers recommend that penicillin G potassium or sodium be given in a dosage of 200,000-300,000 units/kg daily (50,000 units every 4-6 hours) for 10-14 days for the treatment of congenital syphilis diagnosed after the neonatal period or for the treatment of neurosyphilis in infants and children 1 month of age or older.8,9,11,12,292,344 Some clinicians recommend that this regimen be followed by a single dose of IM penicillin G benzathine (50,000 units/kg [up to 2.4 million units]).292,344

For the treatment of neurosyphilis and otic or ocular syphilis in adolescents with human immunodeficiency virus (HIV) infection, some clinicians recommend that IV penicillin G be given a dosage of 18-24 million units daily (by continuous IV infusion or given as 3-4 million units every 4 hours) for 10-14 days.440 Some clinicians recommend that this regimen be followed by a regimen of IM penicillin G benzathine (2.4 million units once weekly for 1-3 weeks).440

HIV-infected neonates with congenital syphilis and HIV-infected children and adolescents with any stage of syphilis should receive the same treatment regimens recommended for those without HIV infection.344,441

Adult Dosage

Bone and Joint Infections

For the treatment of native vertebral osteomyelitis or prosthetic joint infections caused by susceptible β-hemolytic streptococci†, IDSA recommends that adults receive IV penicillin G in a dosage of 20-24 million units daily (by continuous IV infusion or in 6 divided doses).590,591 The recommended duration of treatment is 6 weeks in patients with native vertebral osteomyelitis590 or 4-6 weeks in those with prosthetic joint infections.591

For the treatment of native vertebral osteomyelitis or prosthetic joint infections caused by susceptible Enterococcus †, IDSA recommends that adults receive IV penicillin G in a dosage of 20-24 million units daily (by continuous IV infusion or in 6 divided doses) for 4-6 weeks.590,591 Concomitant treatment with an aminoglycoside given for 4-6 weeks also can be considered591 and is recommended if infective endocarditis also in present.590

For the treatment of native vertebral osteomyelitis or prosthetic joint infections caused by susceptible C. acnes † (formerly P. acnes ), IDSA recommends that adults receive IV penicillin G in a dosage of 20 million units daily (by continuous IV infusion or in 6 divided doses).590,591 The recommended duration of treatment is 6 weeks in patients with native vertebral osteomyelitis590 or 4-6 weeks in those with prosthetic joint infections.591

Endocarditis

For the treatment of native valve endocarditis caused by viridans group streptococci† or S. gallolyticus † (formerly S. bovis ) that are highly penicillin-susceptible (penicillin MIC 0.12 mcg/mL or less), AHA recommends that adults receive IV penicillin G in a dosage of 12-18 million units daily (by continuous IV infusion or in 4 or 6 divided doses) given for 4 weeks.450 Alternatively, adults with uncomplicated endocarditis caused by highly penicillin-susceptible viridans group streptococci† or S. gallolyticus † who are at low risk for adverse effects related to aminoglycoside therapy may receive a 2-week regimen consisting of IV penicillin G in a dosage of 12-18 million units daily (by continuous IV infusion or in 6 divided doses) in conjunction with gentamicin (3 mg/kg daily IV or IM given as a single daily dose or as 1 mg/kg every 8 hours).450 The 2-week regimen is not recommended for patients with known cardiac or extracardiac abscesses, creatinine clearance less than 20 mL/minute, impaired eighth cranial nerve function, or infection with Abiotrophia , Granulicatella , or Gemella .450

For the treatment of native valve endocarditis caused by viridans streptococci† or S. gallolyticus † that are relatively resistant to penicillin G (penicillin MIC greater than 0.12 mcg/mL but less than 0.5 mcg/mL), AHA recommends that adults receive IV penicillin G in a dosage of 24 million units daily (by continuous IV infusion or in 4-6 divided doses) given for 4 weeks in conjunction with gentamicin (3 mg/kg daily IV or IM given as a single daily dose or as 1 mg/kg every 8 hours during the first 2 weeks of penicillin G treatment).450

For the treatment of native valve endocarditis caused by viridans streptococci†, A. defectiva †, or Granulicatella † with penicillin MIC 0.5 mcg/mL or greater, AHA states that IV penicillin G given in a dosage of 18-30 million units daily (by continuous IV infusion or in 6 divided doses) in conjunction with gentamicin (3 mg/kg daily IV or IM in 2 or 3 divided doses) is a reasonable regimen for adults.450 AHA states that consultation with an infectious disease expert is recommended to determine the duration of treatment for such infections.450

For the treatment of endocarditis involving prosthetic valves or other prosthetic material caused by viridans streptococci† or S. gallolyticus † that are highly penicillin-susceptible (penicillin MIC 0.12 mcg/mL or less), AHA states that adults can receive IV penicillin G in a dosage of 24 million units daily (by continuous IV infusion or in 4-6 divided doses) given for 6 weeks with or without gentamicin (3 mg/kg daily IV or IM as a single daily dose or as 1 mg/kg every 8 hours given concomitantly during the first 2 weeks of penicillin G treatment).450 When endocarditis involving prosthetic valves or other prosthetic material is caused by viridans streptococci† or S. gallolyticus † relatively or highly resistant to penicillin G (penicillin MIC greater than 0.12 mcg/mL), AHA states that it is reasonable to extend the duration of concomitant gentamicin to 6 weeks.450

For the treatment of enterococcal endocarditis† (native valve or prosthetic valve or other prosthetic material) caused by Enterococcus susceptible to penicillin and gentamicin, AHA states that adults may receive IV penicillin G in a dosage of 18-30 million units daily (by continuous IV infusion or in 6 divided doses) in conjunction with gentamicin (3 mg/kg daily IV or IM in 2 or 3 divided doses; dose adjusted to achieve gentamicin peak serum concentrations of 3-4 mcg/mL and trough concentrations less than 1 mcg/mL).450 In patients with native valve enterococcal endocarditis, treatment with both drugs should be continued for 4 weeks in those who had symptoms of infection for less than 3 months prior to treatment or for 6 weeks in those who had symptoms for 3 months or longer prior to treatment.450 In patients with enterococcal endocarditis involving prosthetic heart valves or other prosthetic material, continuation of both drugs for 6 weeks is reasonable.450 If endocarditis is caused by enterococci resistant to gentamicin but susceptible to penicillin and streptomycin, AHA states that streptomycin (15 mg/kg daily IV or IM in 2 divided doses; dose adjusted to achieve streptomycin peak serum concentrations of 20-35 mcg/mL and trough concentrations less than 10 mcg/mL) can be substituted for gentamicin in recommended regimens.450 Alternative regimens (e.g., double β-lactam regimens) should be considered in patients with creatinine clearance less than 50 mL/minute.450

The manufacturers state that penicillin G potassium or sodium can be given in a dosage of 5-24 million units daily in divided doses every 4-6 hours for the treatment of endocarditis caused by susceptible staphylococci.8,9,11,12 However, penicillin G is not included in current AHA recommendations for the treatment of staphylococcal endocarditis in adults.450

The manufacturers state that penicillin G potassium or sodium can be given in a dosage of 12-24 million units daily in divided doses every 4-6 hours for the treatment of endocarditis caused by susceptible streptococci, including S. pyogenes , streptococci groups C, H, G, L, and M, and S. pneumoniae .8,9,11,12

Meningitis and Other CNS Infections

For the treatment of meningitis caused by susceptible L. monocytogenes , IDSA and other clinicians recommend that adults receive IV penicillin G in a dosage of 24 million units daily (4 million units every 4 hours).418,475 IDSA recommends a treatment duration of at least 21 days and states that concomitant use of an aminoglycoside should be considered.418 The manufacturers recommend that adults with meningitis caused by susceptible L. monocytogenes receive a penicillin G dosage of 15-20 million units daily given in divided doses every 4-6 hours for 2 weeks.8,9,11

For the treatment of meningitis caused by susceptible N. meningitidis , IDSA recommends that adults receive IV penicillin G in a dosage of 24 million units daily (4 million units every 4 hours) for 7 days.418 The manufacturers recommend that adults receive a dosage of 24 million units daily (2 million units every 2 hours).8,9,11,12

If meningitis is caused by susceptible S. agalactiae † (group B streptococci; GBS), IDSA recommends that adults receive IV penicillin G in a dosage of 24 million units daily (4 million units every 4 hours) for 14-21 days.418 IDSA states that concomitant use of an aminoglycoside should be considered.418

For the treatment of meningitis caused by susceptible S. pneumonia (penicillin MIC less than 0.1 mcg/mL), IDSA and other clinicians recommend that adults receive IV penicillin G in a dosage of 24 million units daily (4 million units every 4 hours) for 10-14 days.418,475 The manufacturers recommend that adults receive a dosage of 12-24 million units daily given in divided doses every 4-6 hours.9,11,12 One manufacturer recommends a dosage of 5-24 million units daily given in divided doses every 4-6 hours.8

For the treatment of healthcare-associated ventriculitis and meningitis caused by C. acnes † (formerly P. acnes ), IDSA recommends that adults receive IV penicillin G in a dosage of 24 million units daily given in divided doses every 4 hours.416 Treatment should be continued for 10 days in those with no or minimal CSF pleocytosis, normal CSF glucose, and few clinical symptoms or systemic features or for 10-14 days in those with significant CSF pleocytosis, CSF hypoglycorrhachia, or clinical symptoms or systemic features.416

Respiratory Tract Infections

If penicillin G potassium or sodium is used for the treatment of serious respiratory tract infections (e.g., empyema, pneumonia) caused by susceptible nonpenicillinase-producing staphylococci, the manufacturers recommend that adults receive a dosage of 5-24 million units daily in divided doses every 4-6 hours depending on severity.8,9,11,12

If penicillin G potassium is used for the treatment of serious respiratory tract infections (e.g., empyema, pneumonia) caused by susceptible S. pyogenes , streptococci groups C, H, G, L, and M, or S. pneumoniae , the manufacturers recommend that adults receive a dosage of 12-24 million units daily in divided doses every 4-6 hours depending on severity.9,11,12 If penicillin G sodium is used for the treatment of these infections, the manufacturer recommends a dosage of 5-24 million units daily in divided doses every 4-6 hours depending on severity.8

Septicemia

If penicillin G potassium or sodium is used for the treatment of septicemia caused by susceptible nonpenicillinase-producing staphylococci, the manufacturers recommend that adults receive a dosage of 5-24 million units daily in divided doses every 4-6 hours depending on severity.8,9,11,12

If penicillin G potassium is used for the treatment of septicemia caused by susceptible S. pyogenes , streptococci groups C, H, G, L, and M, or S. pneumoniae , the manufacturers recommend that adults receive a dosage of 12-24 million units daily in divided doses every 4-6 hours depending on severity.9,11,12 If penicillin G sodium is used for the treatment of these infections, the manufacturer recommends a dosage of 5-24 million units daily in divided doses every 4-6 hours depending on severity.8

Skin and Skin Structure Infections

For the treatment of necrotizing infections of the skin, fascia, and muscle caused by susceptible S. pyogenes , IDSA recommends that adults receive a regimen of IV penicillin G given in a dosage of 2-4 million units every 4-6 hours in conjunction with clindamycin (600-900 mg IV every 8 hours).543

Actinomycosis

For the treatment of actinomycosis caused by Actinomyces in adults, the manufacturers recommend that penicillin G potassium or sodium be given in a dosage of 1-6 million units daily in divided doses every 4-6 hours for cervicofacial disease or 10-20 million units daily in divided doses every 4-6 hours for thoracic or abdominal disease.8,9,11,12

Some clinicians state that, although dosage and duration of therapy should be individualized, a reasonable treatment regimen for pulmonary actinomycosis or other severe infections caused by Actinomyces is IV penicillin G given in a dosage of 18-24 million units daily (3-4 million units every 4 hours) for at least 2-6 weeks followed by 6-12 additional months of an oral regimen (penicillin V or amoxicillin).10,27,28,898,901 A shorter duration of treatment may be sufficient for less extensive disease (e.g., cervicofacial region).10,27,28,29 Surgical procedures should be performed as indicated.8,9,10,11,12,27

Anthrax

For the treatment of anthrax (inhalational, GI, meningitis) caused by penicillin-susceptible B. anthracis that occurs as the result of naturally occurring or endemic anthrax exposure, some clinicians recommend that adults receive IV penicillin G in a dosage of 8-12 million units daily given in divided doses every 4-6 hours.670 For the treatment of severe or life-threatening systemic anthrax (inhalational, GI, meningoencephalitis, sepsis) or the treatment of cutaneous anthrax with signs of systemic involvement or extensive edema caused by penicillin-susceptible B. anthracis that occurs as the result of natural or endemic anthrax exposure, some clinicians recommend that adults receive IV penicillin G in a dosage of 4 million units every 4-6 hours (16-24 million units daily).680 Concomitant use of other anti-infectives (e.g., streptomycin or other aminoglycoside, clindamycin, clarithromycin, rifampin, vancomycin) may also be indicated.670,680 Treatment of naturally occurring or endemic anthrax generally should be continued for at least 14 days after symptoms abate.670

If IV penicillin G is used in a multiple-drug parenteral regimen for initial treatment of systemic anthrax (inhalational, GI, meningitis, cutaneous anthrax with systemic involvement, lesions on the head or neck, or extensive edema) caused by penicillin-susceptible B. anthracis that occurs in the context of biologic warfare or bioterrorism, CDC recommends that adults (including pregnant and postpartum women) receive a dosage of 4 million units every 4 hours.672,673 The multiple-drug parenteral regimen should be continued for at least 2-3 weeks until the patient is clinically stable; treatment can then be switched to an oral regimen.672,673 Because of the possible persistence of anthrax spores in lung tissue following an aerosol exposure in the context of biologic warfare or bioterrorism, CDC and other experts state that the total duration of anti-infective treatment should be 60 days.668,672,673,683,686

The manufacturers state that the minimum dosage of penicillin G potassium or sodium for the treatment of anthrax in adults is 8 million units daily given in divided doses every 6 hours and that higher dosage may be required depending on susceptibility of the organism.8,9,11,12

For additional information on the treatment of anthrax and recommendations for postexposure prophylaxis following exposure to anthrax spores, see Uses: Anthrax, in Ciprofloxacin 8:12.18.

Clostridium Infections

For the treatment of myonecrosis and gas gangrene caused by C. perfringens or other clostridium, IDSA recommends that adults receive IV penicillin G in a dosage of 2-4 million units every 4-6 hours in conjunction with clindamycin (600-900 mg IV every 8 hours).543 The manufacturers recommend that adults receive penicillin G potassium or sodium in a dosage of 20 million units daily given in divided doses every 4-6 hours.8,9,11,12 Surgical debridement and/or surgery should be performed as indicated.8,9,11,12

If penicillin G potassium or sodium is used as an adjunct to TIG in the management of tetanus caused by C. tetani , the manufacturers recommend that adults receive 20 million units daily given in divided doses every 4-6 hours.8,9,11,12 The role of anti-infectives in the adjunctive treatment of tetanus is unclear;10 metronidazole usually is preferred if an anti-infective is used.10,292

If penicillin G potassium or sodium is used as an adjunct in the management of botulism caused by C. botulinum , the manufacturers recommend that adults receive 20 million units daily given in divided doses every 4-6 hours.8,9,11,12 Although the role of anti-infectives is unclear,10,61 some clinicians recommend a penicillin G dosage of 10-20 million units daily for adjunctive management of wound botulism.10 Botulism antitoxin (not commercially available in the US, but may be available from CDC) is the recommended treatment for foodborne and wound botulism and for botulism that occurs in the context of biologic warfare or bioterrorism.10,292,683,746,747,751,753

Diphtheria

If penicillin G potassium or sodium is used as an adjunct to diphtheria antitoxin (not commercially available in the US, but may be available from CDC) for the treatment of diphtheria caused by C. diphtheriae , the manufacturers recommend that adults receive a dosage of 2-3 million units daily given in divided doses every 4-6 hours for 10-12 days.8,9,11,12 CDC recommends a 14-day regimen of IM penicillin G procaine if a penicillin is used for adjunctive treatment of diphtheria.166 Patients usually are no longer contagious 48 hours after initiation of anti-infective treatment.166 Eradication of C. diphtheriae should be confirmed 24 hours after completion of treatment by 2 consecutive negative cultures taken 24 hours apart.166,292

Erysipelothrix Infections

If penicillin G potassium or sodium is used for the treatment of Erysipelothrix endocarditis, the manufacturers recommend that adults receive 12-20 million units daily given in divided doses every 4-6 hours for 4-6 weeks.8,9,11,12

Fusobacterium Infections

If penicillin G potassium or sodium is used for the treatment of severe Fusobacterium infections of the oropharynx (including acute necrotizing ulcerative gingivitis [Vincent's infection], trench mouth, Fusobacterium gingivitis or pharyngitis), lower respiratory tract, or genital area, the manufacturers recommend that adults receive 5-10 million units daily in divided doses every 4-6 hours.8,9,11,12 Penicillin G is not recommended for empiric treatment of such infections because, although the drug may be effective against Fusobacterium , other organisms may also be involved (e.g., Bacteroides fragilis , Prevotella , Porphyromonas ) that usually are resistant to penicillin G.10

Leptospirosis

For the treatment of severe leptospirosis†, IV penicillin G has been given in a dosage of 6 million units daily (1.5 million units every 6 hours) for 7 days.10,98,99 Anti-infective treatment should be initiated as soon as possible after symptom onset;10,292 however, the benefits of anti-infective therapy are uncertain,10,544,545,546 especially if initiated in patients with late and/or severe disease.544,545,546

Listeria Infections

For the treatment of serious infections caused by susceptible L. monocytogenes (e.g., endocarditis, meningitis) in adults, the manufacturers recommend that penicillin G potassium or sodium be given in a dosage of 15-20 million units daily in divided doses every 4-6 hours.8,9,11,12

For additional dosage recommendations regarding the treatment of meningitis caused by L. monocytogenes in adults, see Meningitis and Other CNS Infections under Dosage: Adult Dosage, in Dosage and Administration.

Lyme Disease

If IV penicillin G is used as an alternative to IV ceftriaxone for the treatment of early Lyme disease† in adults with acute neurologic disease manifested as meningitis or radiculopathy, IDSA recommends a dosage of 18-24 million units daily given in divided doses every 4 hours for 10-28 days.329

If IV penicillin G is used as an alternative to IV ceftriaxone for the treatment of late Lyme disease† in adults with recurrent Lyme arthritis and objective evidence of neurologic disease, IDSA recommends a dosage of 18-24 million units daily given in divided doses every 4 hours for 14-28 days.329

For the treatment of late neurologic Lyme disease† affecting the central or peripheral nervous system, IDSA and others state that adults can receive IV penicillin G in a dosage of 18-24 million units daily given in divided doses every 4 hours for 14-28 days as an alternative to IV ceftriaxone.329,342 IDSA states that retreatment is not recommended unless relapse of neurologic disease is documented with reliable objective measures.329

Neisseria meningitidis Infections

For the treatment of septicemia and/or meningitis caused by susceptible N. meningitidis , the manufacturers recommend that adults receive penicillin G potassium or sodium in a dosage of 24 million units daily (2 million units every 2 hours).8,9,11,12

For additional dosage recommendations regarding the treatment of meningitis caused by N. meningitidis in adults, see Meningitis and Other CNS Infections under Dosage: Adult Dosage, in Dosage and Administration.

Pasteurella multocida Infections

For the treatment of serious infections caused by Pasteurella multocida , including bacteremia and meningitis, the manufacturers recommend that adults receive penicillin G potassium or sodium in a dosage of 4-6 million units daily given in divided doses every 4-6 hours for 2 weeks.8,9,11,12

Rat-Bite Fever

For the treatment of rat-bite fever caused by susceptible S. moniliformis (erythema arthriticum epidemicum, Haverhill fever) or S. minus (sodoku), the manufacturers recommend that adults receive penicillin G potassium or sodium in a dosage of 12-20 million units daily given in divided doses every 4-6 hours for 3-4 weeks.8,9,11,12

CDC recommends that adults with rat-bite fever caused by S. moniliformis receive IV penicillin G in a dosage of 1.2 million units daily for 5-7 days; if improvement occurs, treatment can be switched to oral penicillin V or oral ampicillin (500 mg 4 times daily for 7 days).31 Some clinicians suggest that adults with rat-bite fever can receive IV penicillin G in a dosage of 400,000-600,000 units daily for at least 7 days, but that dosage should be increased to 1.2 million units daily if there is no response to the lower dosage within 2 days.30

For the treatment of S. moniliformis endocarditis caused by a strain that is less susceptible to penicillin G (MIC greater than 0.1 mcg/mL), some clinicians recommend that adults receive IV penicillin G in a dosage of 20 million units daily for 4 weeks;10,30 concomitant use of an aminoglycoside (streptomycin or gentamicin) may be indicated for initial treatment.10,30

Syphilis

For the treatment of neurosyphilis and otic or ocular syphilis, CDC and other clinicians recommend that adults receive IV penicillin G in a dosage of 18-24 million units daily (by continuous IV infusion or given as 3-4 million units every 4 hours) for 10-14 days.344,440 Some clinicians recommend that this regimen be followed by a regimen of IM penicillin G benzathine (2.4 million units once weekly for up to 3 weeks).344,440

The manufacturers recommend that adults with neurosyphilis receive penicillin G potassium or sodium in a dosage of 12-24 million units daily (2-4 million units every 4 hours) for 10-14 days;8,9,11,12 this may be followed by a regimen of IM penicillin G benzathine (2.4 million units once weekly for up to 3 weeks).8,9,11,12

HIV-infected adults with any stage of syphilis should receive the same treatment regimens recommended for those without HIV infection.344,440

Whipple's Disease

For initial treatment of Whipple's disease† caused by Tropheryma whipplei , some clinicians recommend that IV penicillin G be given in a dosage of 10 million units daily.10 Others recommend a dosage of 12-24 million units daily (2-4 million units every 4 hours).724 A regimen of IV penicillin G given in a dosage of 1.2 million units daily in conjunction with parenteral streptomycin (1 g daily) also has been recommended.716 The initial parenteral regimen usually is continued for 2-4 weeks and should be followed by 1-2 years of treatment with an oral regimen (e.g., co-trimoxazole).10,716,724

Optimal regimens for treatment of Whipple's disease have not been identified and relapses may occur, even after adequate and long-term anti-infective treatment.10,717,718,719,720

Prevention of Perinatal Group B Streptococcal Disease

When intrapartum anti-infective prophylaxis for prevention of perinatal group B streptococcal (GBS) disease† is indicated in the mother to prevent early-onset GBS disease in her neonate (see Uses: Prevention of Perinatal Group B Streptococcal Disease), CDC and AAP recommend that an initial dose of 5 million units of penicillin G be given IV at the onset of labor or rupture of membranes followed by 2.5-3 million units IV every 4 hours until delivery.292,359,362

Regardless of whether anti-infective prophylaxis was administered to the mother, appropriate diagnostic evaluations and anti-infective therapy should be initiated in the neonate if signs or symptoms of active infection develop.292,359,362

Dosage in Renal and Hepatic Impairment !!navigator!!

In patients with impaired renal function, doses and/or frequency of administration of penicillin G may need to be modified in response to the degree of impairment.8,9,11,12,61,348,369,384,385

The manufacturers state that dosage of IM or IV penicillin G potassium or sodium should be adjusted in patients with severe renal impairment.8,9,11,12 These manufacturers and others recommend that patients with creatinine clearance less than 10 mL/minute per 1.73 m2 receive a loading dose of penicillin G using the usually recommended dose followed by 50% of the usually recommended dose given every 8-10 hours.8,9,11,12,348 In uremic patients with creatinine clearance greater than 10 mL/minute per 1.73 m2, the manufacturers and others recommend a loading dose of penicillin G using the usually recommended dose followed by 50% of the usually recommended dose given every 4-5 hours.8,9,11,12,348

Alternatively, some clinicians suggest that if the usual dosing interval for penicillin G potassium or sodium in patients with normal renal function (creatinine clearance greater than 50 mL/minute) is every 6 or 8 hours, then the usual dose should be given every 8-12 hours in those with creatinine clearance of 10-50 mL/minute or every 12-18 hours in those with creatinine clearance less than 10 mL/minute.61,385

Some clinicians suggest a maximum daily dosage of 4-10 million penicillin G units in adults with severe renal failure.369,384

In patients with impaired hepatic function in addition to impaired renal function, further dosage reductions may be advisable.8,9,11,12,61,348

Cautions ⬆ ⬇

[Section Outline]

Adverse Effects !!navigator!!

Adverse effects reported with penicillin G potassium and penicillin G sodium are similar to those reported with other natural penicillins.8,9,11,12,61

Serious and occasionally fatal hypersensitivity reactions, including anaphylaxis, have been reported with penicillins.8,9,10,11,12,61,611,615,713,769 Hypersensitivity reactions to penicillins may be immediate reactions (usually occurring within 20 minutes after administration) that range in severity from urticaria and pruritus to angioedema, laryngospasm, bronchospasm, hypotension, vascular collapse, and death;8,9,11,12 accelerated reactions (usually occurring between 20 minutes and 48 hours after administration) that may include urticaria, pruritus, fever, and, occasionally, laryngeal edema; or delayed reactions (usually occurring within 1-2 weeks after initiation of penicillin therapy) that may include serum sickness-like symptoms (i.e., fever, malaise, urticaria, myalgia, arthralgia, abdominal pain) and rash ranging from maculopapular eruptions to exfoliative dermatitis.8,9,11,12

Jarisch-Herxheimer reactions may occur in patients receiving penicillin G potassium or sodium for the treatment of syphilis or other spirochetal infections (e.g., leptospirosis†, Lyme disease†, relapsing fever†).8,9,11,12,61

Because of the potassium and sodium content, penicillin G potassium and penicillin G sodium may cause serious and potentially fatal electrolyte disturbances, particularly if high IV dosage is used.8,9,11,12,61 Penicillin G potassium powders for injection contain approximately 66 mg (1.7 mEq) of potassium and approximately 7 mg (0.3 mEq) of sodium in each 1 million units of penicillin G.9,12 Frozen premixed penicillin G potassium injections in dextrose contain approximately 1.7 mEq of potassium and approximately 1 mEq of sodium in each 1 million units of penicillin G.11 Penicillin G sodium powder for injection contains approximately 1.7 mEq of sodium in each 1 million units of penicillin G.8

For additional information on adverse effects reported with penicillin G, see Cautions in the Natural Penicillins General Statement 8:12.16.04.

Precautions and Contraindications !!navigator!!

Penicillin G potassium and sodium are contraindicated in patients hypersensitive to any penicillin.8,9,11,12

The manufacturer of the commercially available frozen premixed penicillin G potassium injections in dextrose states that dextrose-containing solutions may be contraindicated in patients with known allergy to corn or corn products.11

Penicillin G potassium and sodium share the toxic potentials of the penicillins, including the risk of hypersensitivity reactions, and the usual precautions of penicillin therapy should be observed.8,9,11,12

Prior to initiation of therapy with penicillin G potassium or sodium, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other drugs.8,9,11,12 There is clinical and laboratory evidence of partial cross-allergenicity among penicillins and other β-lactam antibiotics including cephalosporins and cephamycins.8,9,11,12,611,615,769,770,779

Hypersensitivity reactions to penicillins are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens.8,9,11,12 Penicillin G potassium or sodium should be used with caution in individuals with a history of allergies and/or asthma.8,9,11,12

If a hypersensitivity reaction occurs, penicillin G should be discontinued immediately and appropriate therapy instituted as indicated (e.g., epinephrine, maintenance of an adequate airway and oxygen, corticosteroids).8,9,11,12 Desensitization has been used to enable a penicillin to be administered to penicillin-hypersensitive patients who have life-threatening infections for which other effective anti-infective agents are not available (e.g., endocarditis, neurosyphilis or congenital syphilis, syphilis during pregnancy).61,64,344,345,350,450,611,615,761,762,763,779 Such procedures are usually performed in a hospital setting and expert consultation may be indicated.344 Specialized references should be consulted for specific information on sensitivity testing and desensitization protocols.344,761,763

During prolonged therapy with high dosage of penicillin G potassium or sodium, the patient's organ system functions should be assessed periodically, including frequent evaluation of hepatic, renal, and hematologic systems, electrolyte balance, and cardiac and vascular status.8,9,11,12 If any impairment of function is suspected or known to exist, a reduction in total dosage should be considered.8,9,11,12 (See Dosage and Administration: Dosage in Renal and Hepatic Impairment.)

For a more complete discussion of these and other precautions associated with the use of penicillin G potassium or sodium, see Cautions: Precautions and Contraindications, in the Natural Penicillins General Statement 8:12.16.04.

Pediatric Precautions !!navigator!!

Renal clearance of penicillin G may be delayed in neonates and premature or young infants because of incompletely developed renal function.8,9,10,11,12,61 Appropriate reductions in dosage and frequency of administration should be made in such patients.8,9,11,12

Neonates receiving penicillin G potassium or sodium should be monitored closely for clinical and laboratory evidence of toxic or adverse effects.8,9,11,12

Geriatric Precautions !!navigator!!

Clinical studies of penicillin G potassium did not include sufficient numbers of patients 65 years of age or older to determine whether geriatric patients respond differently than younger patients.9,11,12 Other clinical experience has not identified differences in responses between geriatric and younger patients.9,11,12

Penicillin G is substantially eliminated by the kidneys and the risk of adverse effects may be greater in those with impaired renal function.9,11,12 Because geriatric patients are more likely to have reduced renal function, dosage should be selected with caution, usually starting at the low end of the dosage range, and renal function monitoring may be useful.9,11,12

The potassium and/or sodium content of penicillin G potassium or sodium preparations and the potential for electrolyte imbalance should be considered.8,9,11,12 Geriatric patients may respond to salt loading with a blunted natriuresis that may be clinically important in those with certain conditions (e.g., congestive heart failure).9,11,12

Pregnancy and Lactation !!navigator!!

Pregnancy

Reproduction studies evaluating penicillin G in mice, rats, and rabbits have not revealed evidence of impaired fertility or harm to the fetus.8,9,11,12,25 Although experience with use of penicillins during pregnancy has not shown any evidence of adverse effects on the fetus, there are no adequate or controlled studies using penicillin G in pregnant women.8,9,11,12

Some clinicians state that penicillin G is considered low risk25 and safe for use during pregnancy.61 The drug is included in the US Centers for Disease Control and Prevention (CDC) recommendations for the treatment of syphilis during pregnancy.344

The manufacturers state that penicillin G potassium or sodium should be used during pregnancy only when clearly needed.8,9,11,12

Lactation

Penicillin G is distributed into milk.8,9,11,12,61,64,355,364,374 Some clinicians state that penicillin G is usually considered compatible with breast-feeding.25 The manufacturers and others state that penicillin G potassium or sodium should be used with caution in nursing women.8,9,11,12,24

Other Information ⬆ ⬇

[Section Outline]

Spectrum

Based on its spectrum of activity, penicillin G is classified as a natural penicillin.10,61,64 For information on the classification of penicillins based on spectra of activity, see the Preface to the General Statements on Penicillins 8:12.16.

For specific information on the spectrum of activity of penicillin G and resistance to the drug, see the sections on Spectrumand on Resistance in the Natural Penicillins General Statement 8:12.16.04.

Pharmacokinetics

For additional information on the absorption, distribution, and elimination of penicillin G, see Pharmacokinetics in the Natural Penicillins General Statement 8:12.16.04.

Absorption !!navigator!!

Penicillin G potassium and penicillin G sodium are rapidly absorbed followed IM administration,9,61,64,70,72 and serum concentrations of penicillin G generally are the same following IM administration of equivalent doses of either salt.64 Following IM administration in adults of a single dose of 600,000 or 1 million units of penicillin G (as either salt), peak serum concentrations of penicillin G generally are attained within 15-30 minutes61,64,70,72 and average 6-8 or 20 units/mL, respectively.61 In one study in neonates 6 days of age or younger who received IM penicillin G in a dosage of 25,000 units/kg every 12 hours as the potassium salt, serum penicillin G concentrations ranged from 12.5-36, 7.8-35.1, 4.4-35.1, 0.7-21.9, and 0.3-9.2 mcg/mL at 30 minutes, 1 hour, 2 hours, 4 hours, and 12 hours, respectively, after a dose.368

Following IV infusion of penicillin G, peak serum concentrations are attained immediately after completion of the infusion.8,9,11,12 In a study in 10 patients who received 5 million units of penicillin G given IV over 3-5 minutes, mean serum concentrations were 400, 273, and 3 mcg/mL at 5-6 minutes, 10 minutes, and 4 hours after administration, respectively.8,9,11,12 In a study in 5 healthy adults who received 1 million units of penicillin G given IV over 4 minutes or 60 minutes, mean serum concentrations 8 minutes after administration were 45 or 14.4 mcg/mL, respectively.8,9,11,12

Following intermittent IV infusion of 2 million units of penicillin G every 2 hours or 3 million units of penicillin G every 3 hours (as either salt), serum penicillin G concentrations reportedly average 20 mcg/mL.61

Penicillin G potassium or sodium is absorbed from the peritoneal cavity following local instillation61,64 and also is absorbed from pleural surfaces, pericardium, and joint cavities.64

Distribution !!navigator!!

Penicillin G is widely distributed throughout the body in varying amounts following parenteral administration.8,9,11,12,61,64,70,81,320 Penicillin G is distributed into the lungs,8,9,11,12 liver,8,9,11,12 kidneys,8,9,11,12 muscle,8,9,11,12 bone,8,9,11,12 and pleural,8,9,11,12 pericardial,9,61 peritoneal,8,9,11,12 ascitic,9,61 synovial,8,9,11,12,61 and interstitial fluids.9 The volume of distribution of penicillin G is reportedly 0.53-0.67 L/kg in adults with normal renal function.340

Minimal concentrations of penicillin G generally are attained in CSF following administration of penicillin G potassium or sodium in patients with uninflamed meninges;8,9,11,12,61,70,320,349,360 however, higher penicillin G concentrations are attained in CSF when the meninges are inflamed.8,9,11,12,61,320,349 Following IV administration of penicillin G sodium, concentrations of penicillin G in CSF reportedly range from 0-10% of concurrent serum concentrations of the drug in patients with normal meninges.360 In 2 adults with syphilis who received a daily IV dosage of 5 or 10 million units of penicillin G (as the potassium salt) for at least 10 days, penicillin G concentrations in CSF immediately following completion of therapy were 0.3 or 2.4 mcg/mL, respectively.360 In one study in children 2 weeks to 11 years of age with meningitis who received penicillin G potassium in a dosage of 250,000 units/kg daily given in 6 divided doses by IV infusion over 15 minutes, penicillin G concentrations in CSF specimens obtained between doses averaged 0.8, 0.7, and 0.3 mcg/mL on the first, fifth, and tenth days of therapy, respectively.349

Penicillin G is approximately 45-68% bound to serum proteins.61,63,64,67,70,81,320,336,337,340,361

Penicillin G crosses the placenta,8,9,11,12,40,61,70,320,362 although cord blood concentrations of the drug may be less than maternal serum concentrations.362

Penicillin G is distributed into milk.8,9,11,12,61,64,355,364,374

Elimination !!navigator!!

The serum half-life of penicillin G in adults with normal renal function is 0.4-0.9 hours.8,9,11,12,61,64,67,81,320,338,340,348,361

Approximately 16-30% of an IM dose of penicillin G sodium is metabolized to penicilloic acid which is microbiologically inactive.366 Small amounts of 6-aminopenicillanic acid (6-APA) have also been found in the urine of patients receiving penicillin G.64,70 In addition, the drug appears to be hydroxylated to a small extent to one or more microbiologically active metabolites which also are excreted in urine.61

Penicillin G and its metabolites are excreted in urine mainly by tubular secretion.8,9,11,12,61,64,70,81,320,348,369 Small amounts of the drug are also excreted in bile.8,9,11,12,61,64,70,81 Following IM or IV administration of a single dose of penicillin G in adults with normal renal function, 58-85% of the dose is excreted in urine as unchanged drug and active metabolites within 6 hours.8,9,11,12,61

Serum concentrations of penicillin G may be higher and the serum half-life prolonged in patients with impaired renal function.8,9,11,12,64,70,81,320,348,369 The serum half-life of the drug is reportedly 1-2 hours in azotemic patients with serum creatinine concentrations less than 3 mg/dL8,9,11,12,348 and ranges from 6-20 hours in anuric patients.8,9,12,64,81,320,348,369 In anuric patients with hepatic impairment, the serum half-life of penicillin G may be 2-3 times more prolonged than in anuric patients with normal hepatic function.70,320,348

Renal clearance of penicillin G is delayed in neonates and premature or young infants.8,9,10,11,12,61 The serum half-life of penicillin G varies inversely with age8,9,11,12,61 and appears to be independent of birthweight.368 The serum half-life of the drug is reportedly 3.2-3.4 hours in neonates 6 days of age or younger, 1.2-2.2 hours in neonates 7-13 days of age, and 0.9-1.9 hours in neonates 14 days of age or older.8,9,11,12,61,368

Renal clearance of penicillin G may be delayed in geriatric patients because of diminished tubular secretion ability.61

Renal clearance of penicillin G may be increased in pregnant women40,61 during the second and third trimesters.40

Penicillin G is removed by hemodialysis8,9,10,11,12,61,63,320,369 and may be removed to a lesser extent by peritoneal dialysis.10

Chemistry and Stability

Chemistry !!navigator!!

Penicillin G is a natural penicillin produced by fermentation of Penicillium chrysogenum in a medium containing phenylacetic acid.61,64,70,72 Penicillin G potassium and penicillin G sodium are frequently referred to as aqueous, crystalline forms of penicillin G.10,61,64,63,72

Penicillin G potassium occurs as colorless or white crystals or a white, crystalline powder that is odorless or practically odorless and moderately hygroscopic.9,12 Penicillin G potassium is very soluble in water.9,12 Penicillin G potassium is commercially available as a sterile powder for injection in vials containing the equivalent of 1, 5, or 20 million units of penicillin G.9,12 Each 1 million units of penicillin G (as penicillin G potassium) contains approximately 66 mg (1.7 mEq) of potassium and approximately 7 mg (0.3 mEq) of sodium.9,12 The sterile powders are buffered with sodium citrate9,12 and/or citric acid.9 Following reconstitution according to the manufacturer's directions, penicillin G potassium solutions have a pH of 6-8.5.9,12 Penicillin G potassium also is commercially available as a frozen premixed solution in dextrose.11

Penicillin G sodium occurs as a white to almost white, crystalline powder that is almost odorless.8 Penicillin G sodium is commercially available as a sterile powder for injection in vials containing the equivalent of 5 million units of penicillin G.8 Each 1 million units of penicillin G (as penicillin G sodium) contains approximately 1.7 mEq of sodium.8 Following reconstitution according to the manufacturer's directions, penicillin G sodium solutions are colorless and have a pH of 5-7.5.8

Commercially available frozen premixed penicillin G potassium injections in dextrose are sterile, iso-osmotic, nonpyrogenic solutions of the drug provided in single-dose plastic containers (Galaxy® containers) fabricated from specially formulated multilayered plastic (PL 2040).11 The frozen injections containing 1, 2, or 3 million units of penicillin G contain approximately 2, 1.2, or 350 mg of dextrose hydrous, respectively, to adjust osmolality and also contain sodium citrate as a buffer.11 Hydrochloric acid and/or sodium hydroxide may have been added to adjust pH to 5.5-8.11 The frozen premixed penicillin G potassium injections in dextrose contain approximately 1.7 mEq of potassium and approximately 1 mEq of sodium in each 1 million units of penicillin G.11

Potency of penicillin G potassium and penicillin G sodium generally is expressed in terms of penicillin G units,8,9,11,12 but also has been expressed as mg of penicillin G.61 Each mg of penicillin G potassium has a potency of 1440-1680 USP penicillin G units;1 each mg of penicillin G potassium powder for injection buffered with sodium citrate has a potency of 1355-1595 USP penicillin G units.1 Each mg of penicillin G sodium has a potency of 1500-1750 USP penicillin G units.1

Stability !!navigator!!

Commercially available penicillin G potassium sterile powder for injection should be stored at less than 30°C.9,12 Following reconstitution, penicillin G potassium solutions should be stored at 2-8°C and are stable for 7 days at this temperature.9,12

Commercially available penicillin G sodium powder for injection should be stored at 20-25°C.8 Following reconstitution, penicillin G sodium solutions should be stored at 2-8°C and are stable for 3 days at this temperature.8

The commercially available frozen premixed penicillin G potassium injections in dextrose should be stored at -20°C or lower.11 The frozen premixed injections should be thawed at room temperature (25°C) or under refrigeration (5°C) and, once thawed, should not be refrozen.11 Thawed solutions of the commercially available frozen injections are stable for 24 hours at room temperature (25°C) or 14 days when refrigerated at 5°C.11 The commercially available frozen injections of the drug are provided in a plastic container fabricated from specially formulated multilayered plastic PL 2040 (Galaxy® containers).11 Solutions in contact with the polyethylene layer can leach out some of its chemical components in very small amounts within the expiration period of the injection; however, safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.11

Penicillin G is unstable in solution at room temperature61 and is rapidly inactivated in carbohydrate solutions at alkaline pH.8,12 Small amounts of polymer conjugation products reportedly form in solutions of penicillin G during in vitro storage, especially when high concentrations of the drug are stored at room temperature.95,96,577 Penicillin degradation products may be more potent antigens than penicillin G and may play a role in hypersensitivity reactions to the drug.61,95,96 Therefore, reconstituted solutions of penicillin G potassium or penicillin G sodium should be refrigerated as directed by the manufacturer8,9,12 or used shortly following reconstitution.61,95,96

Penicillin G is potentially physically and/or chemically incompatible with some drugs, including aminoglycosides and tetracyclines, but the compatibility depends on several factors (e.g., concentrations of the drugs, specific diluents used, resulting pH, temperature).61,300 Specialized references should be consulted for specific compatibility information.300

Additional Information

For further information on chemistry and stability, mechanism of action, spectrum, resistance, pharmacokinetics, uses, cautions, drug interactions, laboratory test interferences, and dosage and administration of penicillin G potassium or sodium, see the Natural Penicillins General Statement 8:12.16.04.

Preparations ⬆ ⬇

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Penicillin G Potassium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

For injection

1 million units (of penicillin G)*

Penicillin G Potassium for Injection

5 million units (of penicillin G)*

Penicillin G Potassium for Injection

Pfizerpen®

Pfizer

20 million units (of penicillin G)*

Penicillin G Potassium for Injection

Pfizerpen®

Pfizer

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Penicillin G Potassium in Dextrose

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

Injection (frozen), for IV infusion

20,000 units (of penicillin G) per mL (1 million units) in 4% Dextrose*

Penicillin G Potassium in Iso-osmotic Dextrose Injection Galaxy®

40,000 units (of penicillin G) per mL (2 million units) in 2.4% Dextrose*

Penicillin G Potassium in Iso-osmotic Dextrose Injection Galaxy®

60,000 units (of penicillin G) per mL (3 million units) in 0.7% Dextrose*

Penicillin G Potassium in Iso-osmotic Dextrose Injection Galaxy®

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Penicillin G Sodium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

For injection

5 million units (of penicillin G)*

Penicillin G Sodium for Injection

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Copyright ⬆ ⬇

AHFS® Drug Information. © Copyright, 1959-2024, Selected Revisions October 1, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, MD 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References ⬆

1. The United States pharmacopeia, 41st rev, and The national formulary, 35th ed. From USP website. Accessed 2018 March 27. [Web]

8. Sandoz. Penicillin G sodium for injection, USP 5 million units prescribing information. Princeton, NJ; 2014 May.

9. Pfizer. Pfizerpen (penicillin G potassium) for injection prescribing information. Princeton, NJ; 2016 Dec.

10. Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015.

11. Baxter Healthcare Corporation. Penicillin G potassium injection, USP for intravenous use only prescribing information. Deerfield, IL; 2017 Nov.

12. WG Critical Care. Penicillin G potassium for injection, USP prescribing information. Paramus, NJ; 2013 Feb.

17. Charles L. Pamplin. Dear healthcare professional letter regarding administration and use of penicillin G benzathine and penicillin G procaine. Bristol, TN: King Pharmaceuticals, Inc; 2004.

18. Centers for Disease Control and Prevention. Inadvertent use of Bicillin® C-R to treat syphilis infection-Los Angeles, CA, 1999-2004. MMWR Morb Mortal Wkly Rep . 2005; 54:217-9. [PubMed 15758893]

24. Tschudy MM, Arcara KM, eds. The Harriet Lane handbook: a manual for pediatric house officers. 19th ed. Philadelphia, PA: Elsevier Mosby; 2012:904-5.

25. Penicillin G and penicillin V. In: Briggs GG, Freeman RK, Towers CV et al. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 11th ed. Philadelphia, PA: Wolters Kluwer Health; 2017:1130-32.

27. Valour F, Sénéchal A, Dupieux C et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist . 2014; 7:183-97. [PubMed 25045274]

28. Sudhakar SS, Ross JJ. Short-term treatment of actinomycosis: two cases and a review. Clin Infect Dis . 2004; 38:444-7. [PubMed 14727221]

29. Reichenbach J, Lopatin U, Mahlaoui N et al. Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis . 2009; 49:1703-10. [PubMed 19874205]

30. Elliott SP. Rat bite fever and Streptobacillus moniliformis. Clin Microbiol Rev . 2007; 20:13-22. [PubMed 17223620]

31. Centers for Disease Control and Prevention (CDC). Fatal rat-bite fever--Florida and Washington, 2003. MMWR Morb Mortal Wkly Rep . 2005; 53:1198-202. [PubMed 15635289]

32. Smego RA, Foglia G. Actinomycosis. Clin Infect Dis . 1998; 26:1255-63. [PubMed 9636842]

35. Antal GM, Lukehart SA, Meheus AZ. The endemic treponematoses. Microbes Infect . 2002; 4:83-94. [PubMed 11825779]

36. Engelkens HJH, Vuzevski VD, Stolz E. Nonvenereal treponematoses in tropical countries. Clin Dermatol . 1999; 19:143-52.

40. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol . 2006; 107:1120-38. [PubMed 16648419]

61. Grayson ML, ed. Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. 7th ed. Boca Raton, FL: CRC Press; 2018:.

63. Neu HC. Penicillins: microbiology, pharmacology, and clinical use. In: Kagan BM, ed. Antimicrobial therapy. 3rd ed. Philadelphia: WB Saunders Company; 1980:20-34.

64. Mandell GL, Sande MA. Antimicrobial agents: penicillins and cephalosporins. In: Gilman AG, Goodman L, Gilman A, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 6th ed. New York: Macmillan Publishing Company; 1980:1126-61.

67. Wilkowske CJ. The penicillins. Mayo Clin Proc . 1977; 52:616-24. [PubMed 242733]

70. Fishman LS, Hewitt WL. The natural penicillins. Med Clin North Am . 1970; 54:1081-99. [PubMed 4248661]

72. Ball AP, Gray JA, Murdoch JM. Antibacterial drugs today: Part I. Drugs . 1975; 10:1-55. [PubMed 1100345]

80. Barza M. Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 2: penicillins. Am J Hosp Pharm . 1977; 34:57-67. [PubMed 318800]

81. Bergan T. Penicillins. In: Schonfeld H, ed. Antibiotics and chemotherapy. Vol 25. Basel: S. Karger; 1978:1-122.

95. Nicholas E, Hess G, Colten HR. Degradation of penicillin, ticarcillin, and carbenicillin resulting from storage of unit doses. N Engl J Med . 1982; 306:547-8. [PubMed 7057866]

96. Neftel KA, Walti M, Spengler H et al. Effect of storage of penicillin-G solutions on sensitization to penicillin-G after intravenous administration. Lancet . 1982; 1:986-7. [PubMed 6122846]

98. Watt G, Padre LP, Tuazon ML et al. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. Lancet . 1988; 1:433-5. [PubMed 2893865]

99. Suputtamongkol Y, Niwattayakul K, Suttinont C et al. An open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis. Clin Infect Dis . 2004; 39:1417-24. [PubMed 15546074]

147. Williamson R, Zighelboim S, Tomasz A. Penicillin-binding proteins of penicillin-resistant and penicillin-tolerant Streptococcus pneumoniae . In: Salton M, Shockman GD, eds. β-Lactam antibiotics: mode of action, new developments, and future prospects. New York: Academic Press; 1981:215-26.

158. Cates KL, Gerrard JM, Giebink GS. A penicillin-resistant pneumococcus. J Pediatr . 1978; 93:624-5. [PubMed 29951]

166. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Washington DC: Public Health Foundation; 2015. Available at CDC website. [Web]

177. Tarpay MM, Welch DF, Salari H et al. In vitro activity of antibiotics commonly used in the treatment of otitis media against Streptococcus pneumoniae isolates with different susceptibilities to penicillin. Antimicrob Agents Chemother . 1982; 22:145-7. [PubMed 6922691]

197. . Drugs for bacterial infections. Treat Guidel Med Lett . 2010; 8:43-52. [PubMed 20489679]

292. American Academy of Pediatrics. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.

297. Duperval R, Bill NJ, Geraci JE et al. Bactericidal activity of combinations of penicillin or clindamycin with gentamicin or streptomycin against species of viridans streptococci. Antimicrob Agents Chemother . 1975; 8:673-6. [PubMed 1211918]

298. Azimi PH, Koranyi K, Lindsey KD. Listeria monocytogenes : synergistic effects of ampicillin and gentamicin. Am J Clin Pathol . 1979; 72:974-7. [PubMed 117697]

300. ASHP's interactive handbook on injectable drugs. McEvoy, GK, ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc; Updated September 29, 2017. From HID website [Web]

302. McDonald LC, Gerding DN, Johnson S et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis . 2018; 66:987-994. [PubMed 29562266]

303. Fekety R for the American College of Gastroenterology Practice parameters Committee. Guidelines for the diagnosis and management of Clostridium difficile - associated diarrhea and colitis. Am J Gastroenterol . 1997; 92:739-50. [PubMed 9149180]

304. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile -associated disease. Am J Health-Syst Pharm . 1998; 55:1407-11. [PubMed 9659970]

305. Feldman WE, Zweighaft T. Effect of ampicillin and chloramphenicol against Streptococcus pneumoniae and Neisseria meningitidis . Antimicrob Agents Chemother . 1979; 15:240-2. [PubMed 34360]

306. Rocco V, Overturf G. Chloramphenicol inhibition of the bactericidal effect of ampicillin against Haemophilus influenzae . Antimicrob Agents Chemother . 1982; 21:349-51. [PubMed 6978674]

320. Barza M, Weinstein L. Pharmacokinetics of the penicillins in man. Clin Pharmacokinet . 1976; 1:297-308. [PubMed 797501]

325. Dunlop EM, Al-Egaily SS, Houang ET. Production of treponemicidal concentration of penicillin in cerebrospinal fluid. BMJ . 1981; 283:646. [PubMed 6790114]

326. Nelson JD. Antibiotic concentrations in septic joint effusions. N Engl J Med . 1971; 284:349-53. [PubMed 5539915]

329. Wormser GP, Dattwyler RJ, Shapiro ED et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis . 2006; 43:1089-134. [PubMed 17029130]

330. Kaplan JM, McCracken GH, Culbertson MC. Penicillin and erythromycin concentrations in tonsils: relevance to treatment failures in streptococcal pharyngitis. Am J Dis Child . 1974; 127:206-11.

336. Kunin CM. Clinical pharmacology of the new penicillins: the importance of serum protein binding in determining antimicrobial activity and concentrations in serum. Clin Pharmacol Ther . 1966; 7:166-79. [PubMed 4956690]

337. Kunin CM. Clinical significance of protein binding of the penicillins. Ann NY Acad Sci . 1967; 145:282-90. [PubMed 4998178]

338. Bergan T, Oydvin B. Cross-over study of penicillin pharmacokinetics after intravenous infusions. Chemotherapy . 1974; 20:263-79. [PubMed 4412673]

339. Gerding DN, Hall WH, Schierl EA. Antibiotic concentrations in ascitic fluid of patients with ascites and bacterial peritonitis. Ann Intern Med . 1977; 86:708-13. [PubMed 869351]

340. Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants: age-related differences and therapeutic implications. Clin Pharmacokinet . 1980; 5:485-527. [PubMed 7002417]

342. Halperin JJ, Shapiro ED, Logigian E et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology . 2007; 69:91-102. [PubMed 17522387]

344. Workowski KA, Bolan GA. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep . 2015; 64(RR-03):1-137. [PubMed 26042815]

345. . Drugs for sexually transmitted infections. Med Lett Drugs Ther . 2017; 59:105-112. [PubMed 28686575]

347. Gibaldi M, Schwartz MA. Apparent effect of probenecid on the distribution of penicillins in man. Clin Pharmacol Ther . 1968; 9:345-9. [PubMed 5649987]

348. Giusti DL. A review of the clinical use of antimicrobial agents in patients with renal and hepatic insufficiency: the penicillins. Drug Intell Clin Pharm . 1973; 7:62-74.

349. Hieber JP, Nelson JD. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med . 1977; 297:410-3. [PubMed 882110]

350. World Health Organization. WHO guidelines for treatment of Treponema pallidum (syphilis). Geneva, Switzerland; WHO; 2016. Available at WHO website. [Web]

354. Dunlop EM, Al-Egaily S, Houang ET. Penicillin levels in blood and CSF achieved by treatment of syphilis. JAMA . 1979; 241:2538-40. [PubMed 374763]

355. Anderson PO. Drugs and breast feeding—a review. Drug Intell Clin Pharm . 1977; 11:208-23.

359. Verani JR, McGee L, Schrag SJ et al. Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep . 2010; 59(RR-10):1-36. [PubMed 21088663]

360. Mohr JA, Griffiths W, Jackson R et al. Neurosyphilis and penicillin levels in cerebrospinal fluid. JAMA . 1976; 236:2208-9. [PubMed 989815]

361. Dittert LW, Griffen WO, LaPiana JC et al. Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration. Antimicrob Agents Chemother . 1969:42-8.

362. Committee on Infectious Diseases, Committee on Fetus and Newborn, Baker CJ et al. Policy statement—Recommendations for the prevention of perinatal group B streptococcal (GBS) disease. Pediatrics . 2011; 128:611-6. [PubMed 21807694]

364. Greene HF, Burkhart B, Hobby GL. Excretion of penicillin in human milk following parturition. J Obstet Gynecol . 1946; 51:732-3.

365. Kaplan JM, McCracken GH. Clinical pharmacology of benzathine penicillin G in neonates with regard to its recommended use in congenital syphilis. J Pediatr . 1973; 82:1069-72.

366. Cole M, Kening MD, Hewitt VA. Metabolism of penicillins to penicilloic acids and 6-aminopenicillanic acid in man and its significance in assessing penicillin absorption. Antimicrob Agents Chemother . 1973; 3:463-8. [PubMed 4364176]

368. McCracken GH, Ginsberg C, Chrane DF et al. Clinical pharmacology of penicillin in newborn infants. Pediatr Pharmacol Ther . 1973; 82:692-8.

369. Bryan CS, Stone WJ. Comparably massive penicillin G therapy in renal failure. Ann Intern Med . 1975; 82:189-95. [PubMed 1115440]

371. Klein JO, Schaberg MJ, Buntin M et al. Levels of penicillin in serum of newborn infants after single intramuscular doses of benzathine penicillin G. Pediatr Pharmacol Ther . 1973; 82:1065-8.

374. Matsuda S. Transfer of antibiotics into maternal milk. Biol Res Pregnancy . 1984; 5:57-60.

384. Bennett WM, Aronoff GR, Morrison G et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis . 1983; 3:155-93. [PubMed 6356890]

385. Jackson EA, McLeod DC. Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part ii. AM J Hosp Pharm . 1974; 31:137-48. [PubMed 4815846]

416. Tunkel AR, Hasbun R, Bhimraj A et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis . 2017; [PubMed 28203777]

418. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis . 2004; 39:1267-84. [PubMed 15494903]

419. Feigin RD, McCracken GH, Klein JO. Diagnosis and management of meningitis. Pediatr Infect Dis J . 1992; 11:785-814. [PubMed 1448332]

475. Quagliarello V, Scheld WM. Treatment of bacterial meningitis. N Engl J Med . 1997; 336:708-16. [PubMed 9041103]

440. Panel on Opportunistic Infection in HIV-infected Adults and Adolescents, US Department of Health and Human Services (HHS). Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed 2018 March 19. Updates may be available at HHS AIDS Information (AIDSinfo) website. [Web]

441. Panel on Opportunistic Infection in HIV-exposed and HIV-infected children, US Department of Health and Human Services (HHS). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Accessed 2018 March 19. Updates may be available at HHS AIDS Information (AIDSinfo) website. [Web]

450. Baddour LM, Wilson WR, Bayer AS et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation . 2015; 132:1435-86. [PubMed 26373316]

452. Baltimore RS, Gewitz M, Baddour LM et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation . 2015; 132:1487-515. [PubMed 26373317]

506. Tunkel AR, Glaser CA, Bloch KC et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis . 2008; 47:303-27. [PubMed 18582201]

512. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis . 2007; 44 Suppl 2:S27-72. Updates may be available at IDSA website at www.idsociety.org. [PubMed 17278083]

513. Bradley JS, Byington CL, Shah SS et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis . 2011; 53:e25-76. Updates may be available at IDSA website at www.idsociety.org. [PubMed 21880587]

543. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis . 2014; 59:147-59. Updates may be available at IDSA website at www.idsociety.org. [PubMed 24947530]

544. Brett-Major DM, Coldren R. Antibiotics for leptospirosis. Cochrane Database Syst Rev . 2012; :CD008264. [PubMed 22336839]

545. Cucinell SA. Early diagnosis and treatment of leptospirosis. Mil Med . 1980; 145:495-7. [PubMed 6772994]

546. Sanford JP. Leptospirosis—time for a booster. N Engl J Med . 1984; 310:524-5. [PubMed 6694697]

547. Shaunak S, Brettle RP, Inglis JM et al. More on leptospirosis. N Engl J Med . 1984; 311:261-2. [PubMed 6738629]

577. Schneider CH. Immunochemistry of penicillin. In: McGovern JP, Stewart GT, eds. Penicillin allergy: clinical and immunologic aspects. Springfield, IL: Charles C Thomas; 1970:23-54.

581. Anderson KC, Maurer MJ, Dajani AS. Pneumococci relatively resistant to penicillin: a prevalence survey in children. J Pediatr . 1980; 97:939-41. [PubMed 6904489]

590. Berbari EF, Kanj SS, Kowalski TJ et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clin Infect Dis . 2015; 61:e26-46. [PubMed 26229122]

591. Osmon DR, Berbari EF, Berendt AR et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis . 2013; 56:e1-e25. [PubMed 23223583]

599. Ekedahl C, Holm SE, Bergholm AM. Penetration of antibiotics into the normal and diseased maxillary sinus mucosa. Scand J Infect Dis . 1978; 14(Suppl):279-84.

611. Idsoe O, Guthe T, Willcox RR et al. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ . 1968; 38:159-88. [PubMed 5302296]

615. Erffmeyer JE. Adverse reactions to penicillin. Ann Allergy . 1981; 47:288-300. [PubMed 6171185]

663. Wright JG, Quinn CP, Shadomy S et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep . 2010; 59(RR-6):1-30. [PubMed 20651644]

668. Inglesby TV, O'Toole T, Henderson DA et al for the Working Group on Civilian Biodefense. Anthrax as a biological weapon 2002: updated recommendations for management. JAMA . 2002; 287:2236-52. [PubMed 11980524]

670. Dixon TC, Meselson M, Guillemin J et al. Anthrax. N Engl J Med . 1999; 341:815-26. [PubMed 10477781]

671. Bradley JS, Peacock G, Krug SE et al. Pediatric anthrax clinical management. Pediatrics . 2014; 133:e1411-36. [PubMed 24777226]

672. Meaney-Delman D, Zotti ME, Creanga AA et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis . 2014; 20:e1-6. [PubMed 24457117]

673. Hendricks KA, Wright ME, Shadomy SV et al. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis . 2014; 20 [PubMed 24447897]

674. Anon. Endemic treponematoses in the 1980s. Lancet . 1983; 2:551-2. [PubMed 6136698]

677. Bryceson AD. Clinical pathology of the Jarisch-Herxheimer reaction. J Infect Dis . 1976; 133:696-704. [PubMed 932495]

680. World Health Organization. Anthrax in human and animals. 4th ed. Geneva, Switzerland: World Health Organization; 2008. From WHO website. Accessed 2018 May 14. [Web]

681. Swartz MN. Recognition and management of anthrax—an update. N Engl J Med . 2001; 345:1621-6. [PubMed 11704686]

682. Centers for Disease Control and Prevention. Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep . 2001; 50:889-93. [PubMed 11686472]

683. US Army Medical Research Institute of Infectious Diseases. USAMRIID's medical management of biologic casualties handbook. 8th ed. Fort Detrick, MD: USAMRIID; 2014 Sep.

686. Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep . 2001; 50:909-19. [PubMed 11699843]

688. Richards ML, Prince RA, Kenaley KA et al. Antimicrobial penetration into cerebrospinal fluid. Drug Intell Clin Pharm . 1981; 15:341-68. [PubMed 7023900]

703. Centers for Disease Control and Prevention. Notice to readers: update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep . 2001; 50:1014-6. [PubMed 11724160]

713. MacFarlane MD, McCarron MM. Anaphylactic shock and anaphylactoid reaction: analysis of 62 cases. Drug Intell Clin Pharm . 1973; 7:394-405.

715. Spark RP. Fatal anaphylaxis due to oral penicillin. Am J Clin Pathol . 1971; 56:407-11. [PubMed 5094502]

716. Fenollar F, Puéchal X, Raoult D. Whipple's disease. N Engl J Med . 2007; 356:55-66. [PubMed 17,202456]

717. Ryser RJ, Locksley RM, Eng SC et al. Reversal of dementia associated with Whipple's disease by trimethoprim-sulfamethoxazole, drugs that penetrate the blood-brain barrier. Gastroenterology . 1984; 86:745-52. [PubMed 6199255]

718. Schmitt BP, Richardson H, Smith E et al. Encephalopathy complicating Whipple's disease: failure to respond to antibiotics. Ann Intern Med . 1981; 94:51-2. [PubMed 6160797]

719. Feldman M, Hendler RS, Morrison EB. Acute meningoencephalitis after withdrawal of antibiotics in Whipple's disease. Ann Intern Med . 1980; 93:709-11. [PubMed 6163384]

720. Singer R. Diagnosis and treatment of Whipple's disease. Drugs . 1998; 55:699-704. [PubMed 9585865]

721. Peters FP, Wouters RS, de Bruine AP et al. Cerebral relapse of sarcoidlike Whipple's disease. Clin Infect Dis . 1997; 24:1252-5. [PubMed 9195094]

722. Schnider PJ, Reisinger EC, Gerschlager W et al. Long-term follow-up in cerebral Whipple's disease. Eur J Gastroenterol Hepatol . 1996; 8:899-903. [PubMed 8889458]

723. Adler CH, Galetta SL. Oculo-facial-skeletal myorhythmia in Whipple disease: treatment with ceftriaxone. Ann Intern Med . 1990; 112:467-9. [PubMed 1689977]

724. Bures J, Kopácová M, Douda T et al. Whipple's Disease: Our Own Experience and Review of the Literature. Gastroenterol Res Pract . 2013; 2013:478349. [PubMed 23843784]

743. Butler T, Jones PK, Wallace CK. Borrelia recurrentis infection: single-dose antibiotic regimens and management of the Jarisch-Herxheimer reaction. J Infect Dis . 1978; 137:573-7. [PubMed 659915]

744. Merson MH, Dowell VR Jr. Epidemiological, clinical and laboratory aspects of wound botulism. N Engl J Med . 1973; 289:1005-10. [PubMed 4582478]

745. Morris JG Jr, Hatheway CL. Botulism in the United States, 1979. J Infect Dis . 1980; 142:302-5.

746. Arnon SS, Schechter R, Inglesby TV et al for the Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA . 2001; 285:1059-70. [PubMed 11209178]

747. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med . 1998; 129:221-8. [PubMed 9696731]

748. Patt HA, Feigin RD. Diagnosis and management of suspected cases of bioterrorism: a pediatric perspective. Pediatrics . 2002; 109:685-92. [PubMed 11927716]

749. Baymiller S. Botulism in critical care: a case study in wound botulism. Am J Crit Care . 2001; 10:172-80. [PubMed 11340740]

750. Schulte M, Hamsen U, Schildhauer TA et al. Effective and rapid treatment of wound botulism, a case report. BMC Surg . 2017; 17:103. [PubMed 29073888]

751. Bossi P, Tegnell A, Baka A et al. Bichat guidelines for the clinical management of botulism and bioterrorism-related botulism. Euro Surveill . 2004; 9:E13-4. [PubMed 15677843]

753. Center for Disease Control and Prevention. Foodborne botulism associated with home-canned bamboo shoots—Thialand, 1998. MMWR Morb Mortal Wkly Rep . 1999; 48:437-9. [PubMed 10372500]

761. Legendre DP, Muzny CA, Marshall GD et al. Antibiotic hypersensitivity reactions and approaches to desensitization. Clin Infect Dis . 2014; 58:1140-8. [PubMed 24368623]

762. Sullivan TJ, Yecies LD, Shatz GS et al. Desensitization of patients allergic to penicillin using orally administered β-lactam antibiotics. J Allergy Clin Immunol . 1982; 69:275-82. [PubMed 7061769]

763. Wendel GD, Stark BJ, Jamison RB et al. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med . 1985; 312:1229-32. [PubMed 3921835]

769. Sullivan TJ, Wedner HJ, Shatz GS et al. Skin testing to detect penicillin allergy. J Allergy Clin Immunol . 1981; 68:171-80. [PubMed 6267115]

770. Saxon A, Beall GN, Rohr AS et al. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med . 1987; 107:204-15. [PubMed 3300459]

779. Kishiyama JL, Adelman DC. The cross-reactivity and immunology of β-lactam antibiotics. Drug Saf . 1994; 10:318-27. [PubMed 8018304]

898. Robbins TS, Scott SA. Actinomycosis: the disease and its treatment. Drug Intell Clin Pharm . 1981; 15:99-102. [PubMed 7274029]

901. de la Monte SM, Gupta PK, White CL. Systemic Actinomyces infection: a potential complication of intrauterine contraceptive devices. JAMA . 1982; 248:1876-7. [PubMed 7120609]

1414. Behrman RE, Vaughn VC III, eds. Nelson textbook of pediatrics. 12th ed. Philadelphia: WB Saunders Company: 1983:403-5,619-25,1823.

1563. Bainbridge CV (Pfipharmecs, New York, NY): Personal communication; 1984 Dec 11.